NCT07841015Not yet recruiting
A Study to Learn More About How Well Finerenone Works in Real-world in People With Type 2 Diabetes and Chronic Kidney Disease in Primary Care (IMSS= Instituto Mexicano Del Seguro Social)
Clinical Profile, Treatment Patterns and Evolution of the Urinary Albumin-to-creatinine Ratio in Patients With Type 2 Diabetes and Chronic Kidney Disease Treated With Finerenone at the Primary Care of the IMSS: Observational, Prospective, Multicenter Study
Source: ClinicalTrials.gov · Last updated 21 Oct 2026
Brief summary (registry, in English)
The main purpose of this study is to learn how treatment with finerenone affects the urinary albumin-to-creatinine ratio (uACR), a marker of kidney health, over time in adults with type 2 diabetes and chronic kidney disease who are receiving care in primary care clinics as part of their usual medical care. The study will help researchers better understand how finerenone is used and how people respond to treatment in everyday primary care settings. This is an observational study, which means the study does not decide or assign treatment. Participants will receive finerenone only if their primary care doctor has already decided to prescribe it as part of routine medical care. The doctor will determine the starting dose and make any dose changes based on the participant's individual needs. All participants will be enrolled in a single study group and followed for up to 12 months after starting finerenone. Information collected during routine primary care visits may include kidney health measurements, laboratory test results, other medications, healthcare use, and any side effects experienced during treatment. Follow-up assessments are planned around Month 1, Month 3, Month 6, and Month 12. Information about adverse events will be collected until 30 days after the participant's last dose of finerenone. The study will not require additional treatment decisions beyond routine care and aims to understand how finerenone performs in real-world primary care practice.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 800 (estimated)
- First submitted
- 3 Sept 2026
- Start date
- 30 Oct 2026
- Primary completion date
- 31 Jan 2028
- Lead sponsor
- Bayer
- Diseases
- Chronic kidney disease, Type 2 diabetes
- NCT number
- NCT07841015
What you commit to
- Study type: Observational
- Planned participants: 800
- From 30 Oct 2026 to the primary completion date, 31 Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant participation in an interventional clinical study involving interventions outside of routine clinical practice at any time during the follow-up period of the present study.
Other
- Contra-indications according to the local label.
Who the study is looking for
- Adult participant - all genders (\>=18 years old).
- Documented diagnosis of Type 2 diabetes (T2D), according to clinical criteria used in routine clinical practice.
- Documented diagnosis of Chronic Kidney Disease (CKD) in stages G2 to G3b, defined by an estimated glomerular filtration rate (Estimated Glomerular Filtration Rate \[eGFR\] \>=30 and \<90 mL/min/1.73 m\^2 according to the information available in the clinical record).
- Baseline urinary albumin-to-creatinine ratio (uACR) value \>=30 mg/g, documented at the time of inclusion in the study.
- Decision to initiate treatment with finerenone made by the physician as part of his or her routine clinical practice and independently of the patient's inclusion in the study.
- Baseline serum potassium \<5.0 mmol/L, determined prior to or at the time of inclusion in the study.
- Signed informed consent.
- Prescription of finerenone within the authorized indications and in accordance with the prescribing information in force in the local market.
- No contraindications to the use of finerenone, in accordance with local marketing authorization and prescribing information in force.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Many locations Coordinator of this site? Confirm its status | Multiple Locations | Mexico | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.